Selected research
Industry Research
Cystic Fibrosis (CF) Therapeutics Industry Research Report 2026
Market perspective
The global Cystic Fibrosis (CF) Therapeutics market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Cystic Fibrosis (CF) Therapeutics market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Cystic Fibrosis (CF) Therapeutics market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Cystic Fibrosis (CF) Therapeutics market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Cystic Fibrosis (CF) Therapeutics include Teva Pharmaceutical Industries Ltd, Novartis AG, Merck & Co., Gilead, AbbVie,, AstraZeneca, Vertex Pharmaceuticalsorporated, F. Hoffmann-La Roche Ltd and ALLERGAN, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Cystic Fibrosis (CF) Therapeutics market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Cystic Fibrosis (CF) Therapeutics.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Cystic Fibrosis (CF) Therapeutics Market by Company
Teva Pharmaceutical Industries Ltd
Novartis AG
Merck & Co.
Gilead
AbbVie,
AstraZeneca
Vertex Pharmaceuticalsorporated
F. Hoffmann-La Roche Ltd
ALLERGAN
Alcresta
Alaxia
AIT (Advanced Inhalation Therapies)
Cystic Fibrosis (CF) Therapeutics Segment by Type
Bronchodilators
Mucolytics
Pancreatic enzyme supplements
CFTR modulators
Cystic Fibrosis (CF) Therapeutics Segment by Application
Oral drugs
Inhaled drugs
Cystic Fibrosis (CF) Therapeutics Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Colombia
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Cystic Fibrosis (CF) Therapeutics market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Cystic Fibrosis (CF) Therapeutics and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Cystic Fibrosis (CF) Therapeutics.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Cystic Fibrosis (CF) Therapeutics companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Bronchodilators
- Mucolytics
- Pancreatic enzyme supplements
- CFTR modulators
Applications
- Oral drugs
- Inhaled drugs
Companies covered
- Teva Pharmaceutical Industries Ltd
- Novartis AG
- Merck & Co.
- Gilead
- AbbVie,
- AstraZeneca
- Vertex Pharmaceuticalsorporated
- F. Hoffmann-La Roche Ltd
- ALLERGAN
- Alcresta
- Alaxia
- AIT (Advanced Inhalation Therapies)
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Cystic Fibrosis (CF) Therapeutics by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Bronchodilators
- 2.2.3 Mucolytics
- 2.2.4 Pancreatic enzyme supplements
- 2.2.5 CFTR modulators
- 2.3 Cystic Fibrosis (CF) Therapeutics by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Oral drugs
- 2.3.3 Inhaled drugs
- 2.4 Assumptions and Limitations
3 Cystic Fibrosis (CF) Therapeutics Breakdown Data by Type
- 3.1 Global Cystic Fibrosis (CF) Therapeutics Historic Market Size by Type (2021-2026)
- 3.2 Global Cystic Fibrosis (CF) Therapeutics Forecasted Market Size by Type (2027-2032)
4 Cystic Fibrosis (CF) Therapeutics Breakdown Data by Application
- 4.1 Global Cystic Fibrosis (CF) Therapeutics Historic Market Size by Application (2021-2026)
- 4.2 Global Cystic Fibrosis (CF) Therapeutics Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Cystic Fibrosis (CF) Therapeutics Market Perspective (2021-2032)
- 5.2 Global Cystic Fibrosis (CF) Therapeutics Growth Trends by Region
- 5.2.1 Global Cystic Fibrosis (CF) Therapeutics Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Cystic Fibrosis (CF) Therapeutics Historic Market Size by Region (2021-2026)
- 5.2.3 Cystic Fibrosis (CF) Therapeutics Forecasted Market Size by Region (2027-2032)
- 5.3 Cystic Fibrosis (CF) Therapeutics Market Dynamics
- 5.3.1 Cystic Fibrosis (CF) Therapeutics Industry Trends
- 5.3.2 Cystic Fibrosis (CF) Therapeutics Market Drivers
- 5.3.3 Cystic Fibrosis (CF) Therapeutics Market Challenges
- 5.3.4 Cystic Fibrosis (CF) Therapeutics Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Cystic Fibrosis (CF) Therapeutics Players by Revenue
- 6.1.1 Global Top Cystic Fibrosis (CF) Therapeutics Players by Revenue (2021-2026)
- 6.1.2 Global Cystic Fibrosis (CF) Therapeutics Revenue Market Share by Players (2021-2026)
- 6.2 Global Cystic Fibrosis (CF) Therapeutics Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Cystic Fibrosis (CF) Therapeutics Head Office and Area Served
- 6.4 Global Cystic Fibrosis (CF) Therapeutics Players, Product Type & Application
- 6.5 Global Cystic Fibrosis (CF) Therapeutics Manufacturers Established Date
- 6.6 Global Cystic Fibrosis (CF) Therapeutics Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Cystic Fibrosis (CF) Therapeutics Market Size (2021-2032)
- 7.2 North America Cystic Fibrosis (CF) Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Cystic Fibrosis (CF) Therapeutics Market Size by Country (2021-2026)
- 7.4 North America Cystic Fibrosis (CF) Therapeutics Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Cystic Fibrosis (CF) Therapeutics Market Size (2021-2032)
- 8.2 Europe Cystic Fibrosis (CF) Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Cystic Fibrosis (CF) Therapeutics Market Size by Country (2021-2026)
- 8.4 Europe Cystic Fibrosis (CF) Therapeutics Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size (2021-2032)
- 9.2 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Cystic Fibrosis (CF) Therapeutics Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Cystic Fibrosis (CF) Therapeutics Market Size (2021-2032)
- 10.2 South America Cystic Fibrosis (CF) Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Cystic Fibrosis (CF) Therapeutics Market Size by Country (2021-2026)
- 10.4 South America Cystic Fibrosis (CF) Therapeutics Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size (2021-2032)
- 11.2 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Cystic Fibrosis (CF) Therapeutics Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Teva Pharmaceutical Industries Ltd
- 12.1.1 Teva Pharmaceutical Industries Ltd Company Information
- 12.1.2 Teva Pharmaceutical Industries Ltd Business Overview
- 12.1.3 Teva Pharmaceutical Industries Ltd Revenue in Cystic Fibrosis (CF) Therapeutics Business (2021-2026)
- 12.1.4 Teva Pharmaceutical Industries Ltd Cystic Fibrosis (CF) Therapeutics Product Portfolio
- 12.1.5 Teva Pharmaceutical Industries Ltd Recent Developments
- 12.2 Novartis AG
- 12.2.1 Novartis AG Company Information
- 12.2.2 Novartis AG Business Overview
- 12.2.3 Novartis AG Revenue in Cystic Fibrosis (CF) Therapeutics Business (2021-2026)
- 12.2.4 Novartis AG Cystic Fibrosis (CF) Therapeutics Product Portfolio
- 12.2.5 Novartis AG Recent Developments
- 12.3 Merck & Co.
- 12.3.1 Merck & Co. Company Information
- 12.3.2 Merck & Co. Business Overview
- 12.3.3 Merck & Co. Revenue in Cystic Fibrosis (CF) Therapeutics Business (2021-2026)
- 12.3.4 Merck & Co. Cystic Fibrosis (CF) Therapeutics Product Portfolio
- 12.3.5 Merck & Co. Recent Developments
- 12.4 Gilead
- 12.4.1 Gilead Company Information
- 12.4.2 Gilead Business Overview
- 12.4.3 Gilead Revenue in Cystic Fibrosis (CF) Therapeutics Business (2021-2026)
- 12.4.4 Gilead Cystic Fibrosis (CF) Therapeutics Product Portfolio
- 12.4.5 Gilead Recent Developments
- 12.5 AbbVie,
- 12.5.1 AbbVie, Company Information
- 12.5.2 AbbVie, Business Overview
- 12.5.3 AbbVie, Revenue in Cystic Fibrosis (CF) Therapeutics Business (2021-2026)
- 12.5.4 AbbVie, Cystic Fibrosis (CF) Therapeutics Product Portfolio
- 12.5.5 AbbVie, Recent Developments
- 12.6 AstraZeneca
- 12.6.1 AstraZeneca Company Information
- 12.6.2 AstraZeneca Business Overview
- 12.6.3 AstraZeneca Revenue in Cystic Fibrosis (CF) Therapeutics Business (2021-2026)
- 12.6.4 AstraZeneca Cystic Fibrosis (CF) Therapeutics Product Portfolio
- 12.6.5 AstraZeneca Recent Developments
- 12.7 Vertex Pharmaceuticalsorporated
- 12.7.1 Vertex Pharmaceuticalsorporated Company Information
- 12.7.2 Vertex Pharmaceuticalsorporated Business Overview
- 12.7.3 Vertex Pharmaceuticalsorporated Revenue in Cystic Fibrosis (CF) Therapeutics Business (2021-2026)
- 12.7.4 Vertex Pharmaceuticalsorporated Cystic Fibrosis (CF) Therapeutics Product Portfolio
- 12.7.5 Vertex Pharmaceuticalsorporated Recent Developments
- 12.8 F. Hoffmann-La Roche Ltd
- 12.8.1 F. Hoffmann-La Roche Ltd Company Information
- 12.8.2 F. Hoffmann-La Roche Ltd Business Overview
- 12.8.3 F. Hoffmann-La Roche Ltd Revenue in Cystic Fibrosis (CF) Therapeutics Business (2021-2026)
- 12.8.4 F. Hoffmann-La Roche Ltd Cystic Fibrosis (CF) Therapeutics Product Portfolio
- 12.8.5 F. Hoffmann-La Roche Ltd Recent Developments
- 12.9 ALLERGAN
- 12.9.1 ALLERGAN Company Information
- 12.9.2 ALLERGAN Business Overview
- 12.9.3 ALLERGAN Revenue in Cystic Fibrosis (CF) Therapeutics Business (2021-2026)
- 12.9.4 ALLERGAN Cystic Fibrosis (CF) Therapeutics Product Portfolio
- 12.9.5 ALLERGAN Recent Developments
- 12.10 Alcresta
- 12.10.1 Alcresta Company Information
- 12.10.2 Alcresta Business Overview
- 12.10.3 Alcresta Revenue in Cystic Fibrosis (CF) Therapeutics Business (2021-2026)
- 12.10.4 Alcresta Cystic Fibrosis (CF) Therapeutics Product Portfolio
- 12.10.5 Alcresta Recent Developments
- 12.11 Alaxia
- 12.11.1 Alaxia Company Information
- 12.11.2 Alaxia Business Overview
- 12.11.3 Alaxia Revenue in Cystic Fibrosis (CF) Therapeutics Business (2021-2026)
- 12.11.4 Alaxia Cystic Fibrosis (CF) Therapeutics Product Portfolio
- 12.11.5 Alaxia Recent Developments
- 12.12 AIT (Advanced Inhalation Therapies)
- 12.12.1 AIT (Advanced Inhalation Therapies) Company Information
- 12.12.2 AIT (Advanced Inhalation Therapies) Business Overview
- 12.12.3 AIT (Advanced Inhalation Therapies) Revenue in Cystic Fibrosis (CF) Therapeutics Business (2021-2026)
- 12.12.4 AIT (Advanced Inhalation Therapies) Cystic Fibrosis (CF) Therapeutics Product Portfolio
- 12.12.5 AIT (Advanced Inhalation Therapies) Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst